Virtual Screening against p50 NF‐κB Transcription Factor for the Identification of Inhibitors of the NF‐κB–DNA Interaction and Expression of NF‐κB Upregulated Genes
2009; Wiley; Volume: 4; Issue: 12 Linguagem: Inglês
10.1002/cmdc.200900362
ISSN1860-7187
AutoresLaura Piccagli, Enrica Fabbri, Monica Borgatti, Nicoletta Bianchi, Valentino Bezzerri, Irene Mancini, Elena Nicolis, Cristina M. Dechecchi, Ilaria Lampronti, Giulio Cabrini, Roberto Gambari,
Tópico(s)RNA regulation and disease
ResumoAbstract Virtual screening against NF‐κB p50 using docking simulations was applied by starting from a three‐dimensional (3D) database containing more than 4.6 million commercially available structures. This database was filtered by specifying a subset of commercially available compounds sharing a (2 E , Z )‐3‐(2‐hydroxyphenyl)‐2‐propenoate substructure and relevant druglike properties. Docking to p50 NF‐κB was performed with a test set of six known inhibitors of NF‐κB–DNA interactions. In agreement with docking results, the highest‐scored compound displayed a high level of inhibitory activity in electrophoretic mobility shift assay (EMSA) experiments (inhibition of NF‐κB–DNA interactions) and on biological functions dependent on NF‐κB activity (inhibition of IL‐8 gene expression in cystic fibrosis IB3‐1 cells). We found that this in silico screening approach is suitable for the identification of low‐molecular‐weight compounds that inhibit NF‐κB–DNA interactions and NF‐κB‐dependent functions. Information deduced from the discovery of the new lead compound and its binding mode could result in further lead optimization resulting in more potent NF‐κB inhibitors.
Referência(s)